ArticleFrontiers in immunology2022
YTHDF1 Negatively Regulates
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Structural and Functional Studies on Key Epigenetic Regulators in Asthma.Biomolecules · 2025Review
- YTHDF1 shapes immune-mediated hepatitis via regulating inflammatory cell recruitment and response.Genes & diseases · 2025Article
- Emerging role of exosomes in cancer therapy: progress and challenges.Molecular cancer · 2025Review
- YTHDF1-mediated m6A modification of GBP4 promotes M1 macrophage polarization in acute lung injury.Respiratory research · 2025Article
- The role of mFrontiers in immunology · 2025Review
- The role of RNA modifications in disease-associated macrophages.Molecular therapy. Nucleic acids · 2024Review
- Phosphorylated vimentin-triggered fibronectin matrix disaggregation enhances the dissemination of Treponema pallidum subsp. pallidum across the microvascular endothelial barrier.PLoS pathogens · 2024Article
- The YTH domain-containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.Clinical and translational medicine · 2024Review
- Review
- Role and regulators of NFrontiers in pharmacology · 2024Review
- Immune-related biomarkers in myocardial infarction; diagnostic/prognostic value and therapeutic potential.Journal of biochemical and molecular toxicology · 2023Review
- Influence of stent-induced vessel deformation on hemodynamic feature of bloodstream inside ICA aneurysms.Biomechanics and modeling in mechanobiology · 2023Article
- Evaluation of Genes and Molecular Pathways Involved in the Progression of Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma: A Systems Biology Approach.Molecular biotechnology · 2023Article
- mMolecular cancer · 2023Review
- The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer.Cell death discovery · 2023Review
- The function and clinical implication of YTHDF1 in the human system development and cancer.Biomarker research · 2023Review
- Experimental and theoretical investigations of Erbium complex: DNA/BSA interaction, anticancer and antibacterial studies.Frontiers in chemistry · 2023Article
- Article
- Neurosyphilis: insights into its pathogenesis, susceptibility, diagnosis, treatment, and prevention.Frontiers in neurology · 2023Review
- The YTHDF1-TRAF6 pathway regulates the neuroinflammatory response and contributes to morphine tolerance and hyperalgesia in the periaqueductal gray.Journal of neuroinflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have confirmed that the bacterium Methods: We first assessed m6A levels in TP-infected macrophages differentiated from the human monocyte cell line THP-1. The binding and interaction between the m6A "writer" methyltransferase-like 3 (METTL3) or the m6A "reader" YT521-B homology (YTH) domain-containing protein YTHDF1 and the suppressor of cytokine signaling 3 (SOCS3), as a major regulator of the inflammatory response, were explored in differentiated TP-infected THP-1 cells as well as in secondary syphilitic lesions from patients. The mechanisms by which YTHDF1 and SOCS3 regulate the inflammatory response in macrophages were assessed. Results and Conclusion: After macrophages were stimulated by TP, YTHDF1 was upregulated in the cells. YTHDF1 was also upregulated in the syphilitic lesions compared to adjacent tissue in patients. YTHDF1 recognizes and binds to the m6A methylation site of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.